drugset / Trial / NCT03904823
A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC
NaSingle-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the efficacy, safety and tolerability of famitinib combined with HS-10296 in subjects with advanced EGFR-mutant NSCLC.
Timeline
- Start
- 2019-04-25
- Primary completion
- 2022-12
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Almonertinib | Small molecule | — | Oral |
| Subject | Famitinib | Small molecule | — | Oral |